SCHEMBL5136261

SCHEMBL5136261

CCCCC(c1cnc(-c2ccccc2)n1CCCC)N(CCCC)Cc1ccc(OC(C)=O)cc1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.35
C5AR1 P21730 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.34
KMT2A Q03164 4/20 0.34
FNTA P49354 1/20 0.34
PGGT1B P53609 1/20 0.34
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
CXCR3 P49682 3/20 0.33
MEN1 O00255 2/20 0.33
POLB P06746 2/20 0.33
PPARD Q03181 1/20 0.33
LMNA P02545 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
AGTR1 P30556 1/20 0.33
AGTR2 P50052 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135337 0.95 TSHR (0.37) TSHRC5AR1LTB4R2KMT2APPARG
SCHEMBL5137324 0.91 ACHE (0.36) TSHRC5AR1CXCR3
SCHEMBL5071417 0.88 TSHR (0.39) TSHRLTB4R2PPARDLMNA
SCHEMBL5135943 0.87 C5AR1 (0.36) TSHRC5AR1KMT2APPARGPPARA
SCHEMBL5136624 0.86 TSHR (0.40) TSHRC5AR1LTB4R2CXCR3
SCHEMBL650145 0.86 LPAR1 (0.40) TSHRKMT2AMEN1AGTR1AGTR2
SCHEMBL5136567 0.85 PPARD (0.38) TSHRPPARGPPARAPPARD
SCHEMBL5136829 0.84 TSHR (0.39) TSHRC5AR1KMT2AMEN1TDP1
SCHEMBL5134552 0.83 TSHR (0.40) TSHRPPARDLMNA
SCHEMBL5135244 0.81 KDM4E (0.35) TSHRC5AR1LTB4R2KMT2ACXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed